People
After Judge Denise Cotes banned Martin Shkreli from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
Jeffrey D. Marrazzo, the co-founder of Spark Therapeutics, is stepping down as CEO of the company. The current COO, Ron Philip, will replace him.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
Proceeds will be used to assemble and develop a diversified pipeline of therapies to address sight-threatening illnesses.
BioSpace covers the Intelligence Squared U.S. debate: Will gene editing enable a healthier, more diverse, more equitable population, or will it create market-born eugenics and a dystopian society?
BioSpace spoke with four veterans in the field about the less obvious reasons why companies with good science may still fail.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES